Cancer Immunotherapy: Imaging Assessment of Novel Treatment Response Patterns and Immune-related Adverse Events
The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
Cancer immunotherapy is changing the imaging evaluation of cancer treatment response and treatment-related toxic effects. New emerging patterns of treatment response and treatment-related toxic effects after treatment with immunomodulating agents have been observed. Treatment response after immunomodulatory therapy can be associated with significantly delayed decrease in tumor size, and new or enlarging tumors observed soon after completion of treatment may not reflect disease progression. In addition, activation of the immune system to fight cancer may lead to unwanted autoimmune-mediated toxic effects that could be mistaken for metastatic disease or misdiagnosed as a non-treatment-related process and delay appropriate clinical management. Radiologists must recognize the novel treatment response patterns and the wide range of autoimmune toxic effects, which should not be mistaken for treatment failure or metastatic disease progression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Cancer immunotherapy comes of age
Mellman, I., Coukos, G., & Dranoff, G. (2011) · Nature · doi:10.1038/nature10673 · Cited by 3,893
Wolchok, J. D., Hoos, A., O'Day, S., Weber, J. S., Hamid, O., Lebbé, C., Maio, M., Binder, M., Bohnsack, O., Nichol, G., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1624 · Cited by 3,222
Attia, P., Phan, G. Q., Maker, A. V., Robinson, M. R., Quezado, M. M., Yang, J. C., Sherry, R. M., Topalian, S. L., Kammula, U. S., Royal, R. E., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.205 · Cited by 1,012
Ott, P. A., Hodi, F. S., & Robert, C. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0143 · Cited by 696
Treatment of metastatic melanoma: an overview.
Bhatia, S., Tykodi, S. S., & Thompson, J. A. (2009) · PubMed · Cited by 666
(2013) · Advances in Cancer Research · doi:10.1016/b978-0-12-407190-2.00007-1 · Cited by 594
CTLA-4 Blockade with Ipilimumab: Long-term Follow-up of 177 Patients with Metastatic Melanoma
Prieto, P. A., Yang, J. C., Sherry, R. M., Hughes, M. S., Kammula, U. S., White, D. E., Levy, C. L., Rosenberg, S. A., & Phan, G. Q. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1823 · Cited by 477
Weber, J. S., Dummer, R., de Pril, V., Lebbé, C., Hodi, F. S., & for the MDX010‐20 Investigators (2013) · Cancer · doi:10.1002/cncr.27969 · Cited by 447
Bronstein, Y., Ng, C. S., Hwu, P., & Hwu, W.-J. (2011) · American Journal of Roentgenology · doi:10.2214/ajr.10.6198 · Cited by 247
Ipilimumab associated hepatitis: imaging and clinicopathologic findings
Kim, K. W., Ramaiya, N. H., Krajewski, K. M., Jagannathan, J. P., Tirumani, S. H., Srivastava, A., & Ibrahim, N. (2013) · Investigational New Drugs · doi:10.1007/s10637-013-9939-6 · Cited by 235
Self-citationKaufman, H. L., Kirkwood, J. M., Hodi, F. S., Agarwala, S., Amatruda, T., Bines, S. D., Clark, J. I., Curti, B., Ernstoff, M. S., Gajewski, T., et al. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.153 · Cited by 196
Schuster, M., Nechansky, A., & Kircheis, R. (2006) · Biotechnology Journal · doi:10.1002/biot.200500044 · Cited by 179
Ipilimumab-Associated Colitis: CT Findings
Kim, K. W., Ramaiya, N. H., Krajewski, K. M., Shinagare, A. B., Howard, S. A., Jagannathan, J. P., & Ibrahim, N. (2013) · American Journal of Roentgenology · doi:10.2214/ajr.12.9751 · Cited by 156
Organizing Pneumonia as a Side Effect of Ipilimumab Treatment of Melanoma
Barjaktarević, I., Qadir, N., Suri, A., Santamauro, J. T., & Stover, D. E. (2013) · CHEST Journal · doi:10.1378/chest.12-1467 · Cited by 116
O'Regan, K. N., Jagannathan, J. P., Ramaiya, N. H., & Hodi, F. S. (2011) · American Journal of Roentgenology · doi:10.2214/ajr.10.6032 · Cited by 93
Immunotherapy for advanced melanoma: Fulfilling the promise
Gogas, H. J., Polyzos, A., & Kirkwood, J. M. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2013.04.006 · Cited by 54
Lymphocytic Vasculitis of the Uterus in a Patient With Melanoma Receiving Ipilimumab
Minor, D. R., Bunker, S. R., & Doyle, J. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.5095 · Cited by 37
Management of toxicities associated with high-dose interleukin-2 and biochemotherapy
Poust, J., Woolery, J. E., & Green, M. R. (2012) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e32835a5ca3 · Cited by 34
In vivo imaging of therapy-induced anti-cancer immune responses in humans
Aarntzen, E. H. J. G., Srinivas, M., Radu, C. G., Punt, C. J. A., Boerman, O. C., Figdor, C. G., Oyen, W. J. G., & de Vries, I. J. M. (2012) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-012-1159-2 · Cited by 26
Cited by
FDG PET/CT-based response assessment in malignancies
Parihar, A. S., Dehdashti, F., & Wahl, R. L. (2023) · RadioGraphics · doi:10.1148/rg.220122 · Cited by 53
“These adverse effects, termed immune-related adverse events, often produce unique imaging findings and can be detected on FDG PET/CT images (46,47).”
Metadata
- Authors
- Kwak, J. J., Tirumani, S. H., Van den Abbeele, A. D., Koo, P. J., & Jacene, H. A.
- Venue
- RadioGraphics
- Published
- 2015-03
- Volume
- 35
- Issue
- 2
- Pages
- 424-437
- ISSN
- 0271-5333 (ISSN-L)
- 1527-1323
- OpenAlex
- W1969062072
- Cited by
- 167
- References
- 21
- FWCI
- 6.24
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.